ERBB2 and gastric cancer: Furthermore, existing well-established biomarkers (e.g., Human epidermal growth factor receptor 2 (HER2) and programmed cell death-ligand 1(PD-L1)) are capable of detecting tumors early and guide specific molecule-based targeted therapy to adjust the characteristics of gastric cancer cells.